Молимо вас користите овај идентификатор за цитирање или овај линк до ове ставке:
https://open.uns.ac.rs/handle/123456789/1299
Назив: | Bioequivalence study of two formulations of itraconazole 100 mg capsules in healthy volunteers under fed conditions: a randomized, three-period, reference-replicated, crossover study | Аутори: | Viktorija Dragojević-Simić Aleksandra Kovačević Vesna Jaćević Nemanja Rančić Snežana Đorđević Vesna Kilibarda Momir Mikov Dubravko Bokonjić |
Кључне речи: | Itraconazole;comparative bioavailability;generic drugs | Датум издавања: | 2-сеп-2018 | Часопис: | Expert Opinion on Drug Metabolism and Toxicology | Сажетак: | © 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group. Background: The aim of the study was to evaluate the bioequivalence of two itraconazole 100 mg capsule formulations. Research design and methods: The single-center, open-label, randomized, three-period, three-sequence, reference-replicated, cross-over study included 38 healthy subjects under fed conditions. In each study period (separated by a 14-day washout), a single oral dose of the test (T) or reference (R) product was administered. Blood samples were collected at pre-dose and up to 72.0 h after administration. The calculated pharmacokinetic parameters, based on the plasma concentrations of itraconazole and hydroxy itraconazole, were AUC0-72h, AUC0-∝, Cmax, Tmax, T1/2 and Kel. Results: The 90% CI for the test/reference geometric means ratio for the parent compound, itraconazole, was in the range from 85.29% to 116.07% for AUC0-72h. Since the coefficient of variation (CV) for the reference product was 44.95% for Cmax, the 90% CI for this parameter for itraconazole was 93.49–133.78%, which was within the proposed limits of the EMA for bioequivalence of 72.15–138.59%. During the study, 4 subjects encountered a total of 14 mild adverse events. Conclusions: The use of the reference-scaling approach with 3-period design (TRR, RTR, and RRT) was an efficient way to demonstrate that two commercially available oral itraconazole formulations met the predetermined bioequivalence criteria. | URI: | https://open.uns.ac.rs/handle/123456789/1299 | ISSN: | 17425255 | DOI: | 10.1080/17425255.2018.1503649 |
Налази се у колекцијама: | MDF Publikacije/Publications |
Приказати целокупан запис ставки
SCOPUSTM
Навођења
6
проверено 15.03.2024.
Преглед/и станица
28
Протекла недеља
0
0
Протекли месец
0
0
проверено 15.03.2024.
Google ScholarTM
Проверите
Алт метрика
Ставке на DSpace-у су заштићене ауторским правима, са свим правима задржаним, осим ако није другачије назначено.